RGNX REGENXBIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, REGENXBIO INC reported revenue of $108M (up 405.7% from a year earlier), net income of $22.7M and diluted EPS of $0.43; over the last four quarters revenue was $174M and net income −$196M; for the fiscal year ended December 2025 revenue was $170M, up 104.5% on the year before.
RGNX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $170M, gross profit n/a, operating income −$161M, net income −$194M (margin -113.8%), EPS −$3.76
- Fiscal year ended Dec 2024: revenue $83.3M, gross profit n/a, operating income −$233M, net income −$227M (margin -272.5%), EPS −$4.59
- Fiscal year ended Dec 2023: revenue $90.2M, gross profit n/a, operating income −$268M, net income −$263M (margin -292.0%), EPS −$6.02
- Fiscal year ended Dec 2022: revenue $113M, gross profit n/a, operating income −$263M, net income −$280M (margin -248.7%), EPS −$6.50
- Fiscal year ended Dec 2021: revenue $470M, gross profit n/a, operating income $160M, net income $128M (margin 27.2%), EPS $2.91
RGNX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $108M (up 405.7% year over year), net income $22.7M, EPS $0.43
- Quarter ended Mar 31, 2026: revenue $6.39M (down 92.8% year over year), net income −$90.1M, EPS −$1.72
- Quarter ended Dec 31, 2025 (from the annual report): revenue $30.3M (up 43.0% year over year), net income −$67.1M, EPS −$1.30
- Quarter ended Sep 30, 2025: revenue $29.7M (up 22.9% year over year), net income −$61.9M, EPS −$1.20
- Quarter ended Jun 30, 2025: revenue $21.4M (down 4.2% year over year), net income −$70.9M, EPS −$1.38
- Quarter ended Mar 31, 2025: revenue $89.0M (up 469.8% year over year), net income $6.08M, EPS $0.12
- Quarter ended Dec 31, 2024 (from the annual report): revenue $21.2M (down 4.5% year over year), net income −$51.2M, EPS −$0.99
- Quarter ended Sep 30, 2024: revenue $24.2M (down 16.3% year over year), net income −$59.6M, EPS −$1.17
- Quarter ended Jun 30, 2024: revenue $22.3M (up 11.6% year over year), net income −$53.0M, EPS −$1.05
- Quarter ended Mar 31, 2024: revenue $15.6M (down 18.4% year over year), net income −$63.3M, EPS −$1.38
- Quarter ended Dec 31, 2023 (from the annual report): revenue $22.2M (down 29.1% year over year), net income −$62.9M, EPS −$1.42
- Quarter ended Sep 30, 2023: revenue $28.9M (up 9.1% year over year), net income −$61.9M, EPS −$1.41
- Quarter ended Jun 30, 2023: revenue $20.0M (down 38.8% year over year), net income −$72.1M, EPS −$1.66
- Quarter ended Mar 31, 2023: revenue $19.1M (down 13.9% year over year), net income −$66.7M, EPS −$1.53
- Quarter ended Dec 31, 2022 (from the annual report): revenue $31.3M (down 92.1% year over year), net income −$59.9M, EPS −$1.38
- Quarter ended Sep 30, 2022: revenue $26.5M (down 13.8% year over year), net income −$75.5M, EPS −$1.75
- Quarter ended Jun 30, 2022: revenue $32.6M (up 48.2% year over year), net income −$68.2M, EPS −$1.58
- Quarter ended Mar 31, 2022: revenue $22.2M (up 17.7% year over year), net income −$76.7M, EPS −$1.79
- Quarter ended Dec 31, 2021 (from the annual report): revenue $399M, net income $294M, EPS $6.84
- Quarter ended Sep 30, 2021: revenue $30.8M, net income −$58.4M, EPS −$1.37
RGNX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$124M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$173M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$218M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$207M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $219M, share buybacks n/a
RGNX balance sheet
- Jun 30, 2026: cash $36.5M, total assets $387M, total liabilities $315M, shareholders' equity $71.8M
- Mar 31, 2026: cash $15.2M, total assets $342M, total liabilities $321M, shareholders' equity $21.1M
- Dec 31, 2025: cash $34.5M, total assets $453M, total liabilities $350M, shareholders' equity $103M
- Sep 30, 2025: cash $58.8M, total assets $525M, total liabilities $364M, shareholders' equity $161M
- Jun 30, 2025: cash $79.6M, total assets $581M, total liabilities $367M, shareholders' equity $214M
- Mar 31, 2025: cash $130M, total assets $491M, total liabilities $217M, shareholders' equity $274M
- Dec 31, 2024: cash $57.5M, total assets $466M, total liabilities $206M, shareholders' equity $260M
- Sep 30, 2024: cash $56.6M, total assets $519M, total liabilities $218M, shareholders' equity $301M
What is RGNX's revenue?
REGENXBIO INC reported $174M of revenue over its last four quarters, through June 30, 2026.
Is RGNX profitable?
No. REGENXBIO INC lost $196M over the last four quarters.
What is RGNX's EPS?
Diluted earnings per share over the last four quarters were −$3.79; $0.43 in the latest quarter.